This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Obesity is a recognized public health epidemic with a prevalence that continues to increase dramatically in nearly all populations, impeding progress in reducing incidence rates of cardiovascular disease. Circulation, Ahead of Print.
The session will detail the results of a webcast series on better managing obesity in patients with type 2 diabetes, significantly improving their knowledge and treatment practices. The program led to increases in knowledge and competence regarding new weight management therapies and effective long-term obesity treatment.
The panelists stress the significance of a comprehensive approach to patientcare, acknowledging the interconnected nature of cardiovascular, kidney, endocrine, and obesity-related benefits, and highlighting that addressing secondary diseases can minimize overall disease risk in patients.
A jam-packed, expertly curated agenda will highlight the latest and most impactful advancements in cardiorenal metabolic medicine and protocols for future-focused, whole-patientcare.
2023, the American Heart Association (AHA) issued a presidential advisory on the urgency of this systemic disorder involving heart disease, kidney disease, diabetes and obesity. In its advisory, the AHA stressed an interdisciplinary team approach emphasizing social determinants of health, shortcomings in current efforts, and knowledge gaps.
These advancements, alongside software enhancements, enable early detection of cardiac diseases, empowering healthcare providers to make evidence-based decisions and tailor appropriate patientcare plans. GEMMSOne seamlessly integrates with different medical devices.
Aronne, MD , discussed advances in obesity pharmacology, while Virend K. Until next year, let’s continue advancing cardiometabolic health education and improving patientcare. Best of the 19th Annual CMHC Previous slide Next slide Experts like Louis J.
Singh, MBBS, FRCP, MBA Advances in Obesity Pharmacotherapy Louis J. Aronne, MD Expert Perspectives on Initiating and Maintaining Insulin Therapy in Type 2 Diabetes Patients Jay H. To apply, click here or go to www.cardiometabolichealth.org/george-bakris-scholarship-program/ NEW! Contact Data Megan Magana, Sr.
Depending on who you talk to, we could be headed towards a completely new anticoagulation standard of care. Prevention & Detection – Boosted by GLP-1 obesity buzz and the fact that cardiovascular outcome trends have been headed in the wrong direction, AHA 2023 placed a greater focus on prevention.
24 and how those may impact clinical practice and patientcare in this deep dive clinical trial session. ET Murphy Ballroom 4 ACC.24 24 planners note that attendees can gain insights from key clinical trials presented at ACC.24 More information: www.acc.org If you enjoy this content, please share it with a colleague
The patient underwent both FDG‐PET/CT and NaF‐PET/CT imaging. While these findings provide preliminary insight, further research is crucial to corroborate our results and delineate their potentially transformative implications on patientcare, particularly in the context of surgical interventions.
Tirzepatide Approval Date: December 19, 2024 Indication: Moderate to severe obstructive sleep apnea (OSA) in adults with obesity, combined with a reduced-calorie diet and increased physical activity. To explore FDA approvals from January to July 2024, click here.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content